This breakthrough treatment uses advanced asymmetric small interfering RNA (siRNA) technology to directly target and degrade the genetic messenger RNA (mRNA) responsible for building androgen receptors in the scalp. By silencing androgen receptor expression at the gene level rather than suppressing circulating hormones, OLX104C stops hair loss at its source. In preclinical testing, a single local dose provided continuous gene muting for more than three weeks, attracting a major R&D partnership and strategic investment from L’Oréal’s corporate venture fund.
What Is It and How Does It Work?
OLX104C is a specialized gene-silencing therapeutic administered via localized intradermal micro-injections or topical delivery into the balding scalp.
It works through a cutting-edge process called Asymmetric siRNA-Mediated Androgen Receptor mRNA Degradation:
-
The Genetic Blueprint: Hair loss occurs when dihydrotestosterone (DHT) attaches to androgen receptors (AR) inside hair follicle cells, triggering inflammatory signals that shrink the follicle. Traditional pills try to block DHT throughout the body, which can cause systemic hormonal side effects.
-
Asymmetric siRNA Platform: OLX104C utilizes OliX’s proprietary cell-penetrating asymmetric siRNA (cp-siRNA) technology. These custom-engineered RNA strands easily pass through skin cell membranes.
-
Muting the Receptor Gene: Once inside the scalp cells, the siRNA molecules bind to and destroy messenger RNA (mRNA) carrying instructions to produce androgen receptors.
-
Targeted Protection: Without androgen receptors available, DHT cannot attach to the hair roots. Because the siRNA stays anchored in the scalp tissue and does not alter systemic hormone production, it eliminates the risk of sexual dysfunction, depression, or hormonal imbalances associated with daily oral medications.
The Science: Long-Lasting Local Efficacy and L’Oréal Strategic Backing
The Phase 1b/2a human clinical trial, currently being conducted in Australia, was designed to evaluate the safety, tolerability, and duration of androgen receptor knockdown in human scalps.
Key clinical and preclinical highlights include:
-
Extended Single-Dose Duration: Preclinical testing on human skin models demonstrated that a single localized dose of OLX104C maintained effective androgen receptor silencing for more than three weeks. This long-acting profile opens the possibility for a treatment given just once or twice a month.
-
L’Oréal R&D Partnership: The technology’s ability to selectively silence hair loss genes without hormonal side effects led L’Oréal’s corporate venture fund (BOLD) to invest directly in OliX Pharmaceuticals and sign a joint R&D agreement focused on skin and hair regeneration.
-
Flawless Hormonal Safety: Because the treatment works via localized mRNA degradation rather than systemic enzyme inhibition, blood testing confirmed zero reduction in systemic testosterone or DHT levels.
“siRNA technology inhibits gene expression by targeting and degrading messenger RNA, blocking the production of proteins that cause hair loss… In the field of hair loss, siRNA has the unique advantage of regulating the core causes of androgenetic alopecia at the genetic level without hormone-related side effects.” — OliX Pharmaceuticals Research Summary.
When Will It Be Available?
-
Current Stage: OLX104C is currently undergoing Phase 1b/2a clinical trials in Australia.
Read next
Whats the best shampoo for hair loss?
-
Timeline: OliX Pharmaceuticals aims to complete the Phase 1b safety evaluation and advance through Phase 2a efficacy readouts. With strategic guidance and commercialization support from L’Oréal, the treatment could enter Phase 3 trials and aim for pharmacy release around 2028 or 2029.
How you can benefit from this treatment now
While OLX104C completes its Phase 1b/2a clinical trials, you can leverage these gene-silencing insights today:
-
Explore Available RNA-Based Tonics: The success of RNA interference for hair loss has validated topical RNA tonics. Patients in Europe can look into approved cosmetic siRNA tonics (such as CosmeRNA ARI) that utilize similar messenger RNA silencing principles to reduce androgen receptor sensitivity without daily pills.
-
Monitor Australian Trial Enrollments: If you are located in Australia or able to travel, you can track active trial sites for OliX Pharmaceuticals OLX104C on local clinical trial registries to see if you qualify to participate in upcoming trial cohorts.
-
Focus on Non-Systemic Anti-Androgens: If you are sensitive to oral hormone blockers, talk to a dermatologist about localized anti-androgen options (such as topical clascoterone/Breezula or intradermal dutasteride mesotherapy) that target the scalp locally while minimizing systemic side effects.
Sources: